Herein we build on our original report by contrasting the functional, transcriptional, and pharmacological properties of the ESR1-e6>YAP1 fusion with additional ESR1 gene fusion events identified by RNA-seq of both early-stage and metastatic ER+ breast cancers. Here, YAP1 is linked to breast cancer.